Organ-on-a-Chip is a powerful technology driving physiological relevance by utilizing microfluidic techniques. The technology is expected to impact drug development and ultimately replace or reduce animal testing. Since the majority of platform technologies are either based on single or small numbers of chips in dedicated surroundings, applications for Organ-on-a-Chip are largely envisioned in pre-clinical testing, such as preclinical safety, pharmacology, or pharmacokinetics. Thus far it was thought that the advanced complexity of models limits scalability and thus their utility for drug discovery studies. Until now.
In this session, Dr. Kristin Bircsak (MIMETAS), Dr. Angeline Lim (Molecular Devices), and Dr. Alessandro Prestipino (Merck Healthcare) explain how Organ-on-a-Chip technology enables scientists to develop physiologically relevant human (disease) models in a platform being fully compatible with automated imaging and robotic handling.